Celgene Stock Total Asset
Celgene fundamentals help investors to digest information that contributes to Celgene's financial success or failures. It also enables traders to predict the movement of Celgene Stock. The fundamental analysis module provides a way to measure Celgene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Celgene stock.
Celgene |
Celgene Company Total Asset Analysis
Celgene's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Celgene Total Asset | 1.11 B |
Most of Celgene's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Celgene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
CompetitionBased on the latest financial disclosure, Celgene has a Total Asset of 1.11 B. This is 85.27% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The total asset for all United States stocks is 96.24% higher than that of the company.
Celgene Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Celgene's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Celgene could also be used in its relative valuation, which is a method of valuing Celgene by comparing valuation metrics of similar companies.Celgene is currently under evaluation in total asset category among its peers.
Celgene Fundamentals
| Return On Equity | 1.0E-4 | |||
| Return On Asset | 0.14 | |||
| Profit Margin | 0.30 % | |||
| Operating Margin | 51.47 % | |||
| Current Valuation | 85.34 B | |||
| Shares Outstanding | 708.74 M | |||
| Shares Owned By Insiders | 0.22 % | |||
| Shares Owned By Institutions | 77.62 % | |||
| Number Of Shares Shorted | 12.95 M | |||
| Price To Earning | 13.31 X | |||
| Price To Book | 7.45 X | |||
| Price To Sales | 4.54 X | |||
| Revenue | 16.35 B | |||
| Gross Profit | 14.06 B | |||
| EBITDA | 8.42 B | |||
| Net Income | 5.27 B | |||
| Cash And Equivalents | 9.32 B | |||
| Cash Per Share | 13.15 X | |||
| Total Debt | 20.1 B | |||
| Debt To Equity | 199.90 % | |||
| Current Ratio | 3.44 X | |||
| Book Value Per Share | 9.22 X | |||
| Cash Flow From Operations | 6.35 B | |||
| Short Ratio | 3.45 X | |||
| Earnings Per Share | 7.32 X | |||
| Price To Earnings To Growth | 0.67 X | |||
| Number Of Employees | 8.85 K | |||
| Beta | 1.41 | |||
| Market Capitalization | 77.04 B | |||
| Total Asset | 1.11 B | |||
| Retained Earnings | 21.79 B | |||
| Working Capital | 708.47 M | |||
| Current Asset | 849.88 M | |||
| Current Liabilities | 141.41 M | |||
| Z Score | 69.79 |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Celgene Stock
If you are still planning to invest in Celgene check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Celgene's history and understand the potential risks before investing.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |